首页 > 最新文献

Journal of Vascular Surgery最新文献

英文 中文
Neuroophthalmic outcomes following carotid intervention for ocular symptoms. 颈动脉介入治疗眼部症状后的神经眼科效果。
IF 3.9 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-19 DOI: 10.1016/j.jvs.2024.11.015
Boshra Al Ibraheem, Tiziano Tallarita, Sasha A Mansukhani, Mokhshan Ramachandran, James Manz, Jenny Lau, Bayan Moustafa, Andrew D Calvin, Thomas Carmody, Indrani Sen

Introduction: The long term neuroophthalmic outcomes following carotid intervention in patients presenting with pre-operative visual symptoms vary widely based on the underlying etiology of retinal ischemia and are not well understood.

Methods: We performed a retrospective review of consecutive patients presenting with retinal ischemia who subsequently underwent carotid intervention from January 2018 to December 2022. Patients were classified into three groups [Group I: Amaurosis fugax (AF)/ vascular transient monocular vision loss (TMVL), Group II: Ocular Ischemic Syndrome (OIS) and Group III: Central/Branch Retinal Artery Occlusion (C/BRAO)]. Clinical details and the nature of visual symptoms were recorded. Outcomes analyzed were ipsilateral symptom recurrence, visual improvement, stroke rate and survival.

Results: There were 90 patients included in this study (70 male, 75+ 9 years); 31 patients (34%) in Group I (AF), 7 patients (8%) in Group II(OIS), and 52 patients (58%) in Group III (C/BRAO). Atherosclerotic risk factors were similar across groups with similar preoperative antiplatelet and statin use. Interventions performed were carotid endarterectomy in 64 (71%), transfemoral carotid artery stenting in 21 (23%), transcarotid artery revascularization in 4 (4%) and carotid artery bypass in one patient (1%). Median follow-up was 38.5 months (range 0- 207 months). There was no recurrence of transient or permanent retinal ischemic events in any patient in the Group I. In Group II, 5 of 7 patients presenting with transient symptoms of OIS showed resolution of symptoms and ocular signs. Two patients presenting with permanent vision loss in Group II had no improvement but no worsening symptoms, and visual decline was reported in two patients in Group III. Ipsilateral stroke rate was 2% at 5 years for the entire group. Survival was 93% and 82% at 1 and 5 years, with no difference between groups (p<0.05) There was 1 post-operative death from ischemic stroke secondary to stent thrombosis within 30 days (Group III), with no long-term mortality from cerebrovascular disease in the rest of the cohort.

Conclusions: Neuro-ophthalmic outcomes following carotid intervention for visual symptoms is favorable with low symptomatic recurrence following both carotid endarterectomy and carotid artery stenting. Intervention for OIS when detected early (with transient symptoms) is associated with resolution of symptoms and prevention of permanent visual loss.

导言:根据视网膜缺血的潜在病因,对术前出现视力症状的患者进行颈动脉介入治疗后,神经眼科的长期预后差异很大,目前尚不十分清楚:我们对2018年1月至2022年12月期间出现视网膜缺血并随后接受颈动脉介入治疗的连续患者进行了回顾性回顾。患者被分为三组[I组:Amaurosis fugax(AF)/血管性短暂单眼视力丧失(TMVL),II组:眼部缺血综合征(OIS),III组:视网膜中央/分支动脉闭塞(C/BRAO)]。记录了临床细节和视觉症状的性质。分析结果包括同侧症状复发、视力改善、中风率和存活率:本研究共纳入 90 名患者(70 名男性,75+ 9 岁),其中 31 名患者(34%)属于第一组(房颤),7 名患者(8%)属于第二组(OIS),52 名患者(58%)属于第三组(C/BRAO)。各组的动脉粥样硬化风险因素相似,术前服用抗血小板药物和他汀类药物的情况也相似。64名患者(71%)接受了颈动脉内膜切除术,21名患者(23%)接受了经股动脉颈动脉支架植入术,4名患者(4%)接受了经颈动脉血运重建术,1名患者(1%)接受了颈动脉搭桥术。中位随访时间为 38.5 个月(0-207 个月)。第一组中没有任何患者再次发生一过性或永久性视网膜缺血事件。第二组中出现永久性视力丧失的两名患者的症状没有改善但也没有恶化,第三组中有两名患者出现视力下降。整组患者 5 年的同侧中风率为 2%。1年和5年的存活率分别为93%和82%,组间无差异(P结论:颈动脉内膜切除术和颈动脉支架术后症状复发率都很低,因此对视觉症状进行颈动脉介入治疗后可获得良好的神经眼科效果。如果早期发现(有短暂症状),对 OIS 进行干预可缓解症状并防止永久性视力丧失。
{"title":"Neuroophthalmic outcomes following carotid intervention for ocular symptoms.","authors":"Boshra Al Ibraheem, Tiziano Tallarita, Sasha A Mansukhani, Mokhshan Ramachandran, James Manz, Jenny Lau, Bayan Moustafa, Andrew D Calvin, Thomas Carmody, Indrani Sen","doi":"10.1016/j.jvs.2024.11.015","DOIUrl":"https://doi.org/10.1016/j.jvs.2024.11.015","url":null,"abstract":"<p><strong>Introduction: </strong>The long term neuroophthalmic outcomes following carotid intervention in patients presenting with pre-operative visual symptoms vary widely based on the underlying etiology of retinal ischemia and are not well understood.</p><p><strong>Methods: </strong>We performed a retrospective review of consecutive patients presenting with retinal ischemia who subsequently underwent carotid intervention from January 2018 to December 2022. Patients were classified into three groups [Group I: Amaurosis fugax (AF)/ vascular transient monocular vision loss (TMVL), Group II: Ocular Ischemic Syndrome (OIS) and Group III: Central/Branch Retinal Artery Occlusion (C/BRAO)]. Clinical details and the nature of visual symptoms were recorded. Outcomes analyzed were ipsilateral symptom recurrence, visual improvement, stroke rate and survival.</p><p><strong>Results: </strong>There were 90 patients included in this study (70 male, 75+ 9 years); 31 patients (34%) in Group I (AF), 7 patients (8%) in Group II(OIS), and 52 patients (58%) in Group III (C/BRAO). Atherosclerotic risk factors were similar across groups with similar preoperative antiplatelet and statin use. Interventions performed were carotid endarterectomy in 64 (71%), transfemoral carotid artery stenting in 21 (23%), transcarotid artery revascularization in 4 (4%) and carotid artery bypass in one patient (1%). Median follow-up was 38.5 months (range 0- 207 months). There was no recurrence of transient or permanent retinal ischemic events in any patient in the Group I. In Group II, 5 of 7 patients presenting with transient symptoms of OIS showed resolution of symptoms and ocular signs. Two patients presenting with permanent vision loss in Group II had no improvement but no worsening symptoms, and visual decline was reported in two patients in Group III. Ipsilateral stroke rate was 2% at 5 years for the entire group. Survival was 93% and 82% at 1 and 5 years, with no difference between groups (p<0.05) There was 1 post-operative death from ischemic stroke secondary to stent thrombosis within 30 days (Group III), with no long-term mortality from cerebrovascular disease in the rest of the cohort.</p><p><strong>Conclusions: </strong>Neuro-ophthalmic outcomes following carotid intervention for visual symptoms is favorable with low symptomatic recurrence following both carotid endarterectomy and carotid artery stenting. Intervention for OIS when detected early (with transient symptoms) is associated with resolution of symptoms and prevention of permanent visual loss.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence and Predictors of Gastrointestinal Hemorrhage following Mesenteric Revascularization. 肠系膜血管重建术后消化道出血的发生率和预测因素
IF 3.9 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-18 DOI: 10.1016/j.jvs.2024.11.006
Armin Farazdaghi, Diego V S Rodrigues, Claire Cassianni, Jill J Colglazier, Gustavo S Oderich, Manju Kalra, Fahad Shuja, Melinda Schaller, Todd Rasmussen, Randall R DeMartino, Bernardo C Mendes

Objectives: Post-operative gastrointestinal hemorrhage (GIH) following mesenteric revascularization when performed either open (OR) or endovascularly (ER) has been clinically observed but not reported. The aim of the study is to assess the incidence and predictors of GIH in patients undergoing mesenteric revascularization.

Methods: Single-center retrospective review of consecutive patients treated with open or endovascular mesenteric revascularization from 2009-2019. Patients with non-occlusive mesenteric ischemia, intraoperative or perioperative death within 24 hours, or no post-operative follow-up were excluded. Primary endpoints were incidence and predictors of clinically significant GIH within 30- and 60 days postoperatively. Clinically significant GIH (CS-GIH) was defined if patients required RBC transfusion, hospital re-admission, escalation to intensive care, prolonged discontinuation of anticoagulation, or need for endoscopy/colonoscopy.

Results: A total of 260 patients presented with mesenteric ischemia and underwent OR/ER. 205 patients met inclusion criteria (139 female [68%], mean age of 69.9 years [range 18-92 years]). Presentation was chronic mesenteric ischemia in 128 patients (62%), acute-on-chronic in 45 (22%) and acute in 32 (16%). 93 (45%) underwent OR, 93 (45%) ER, and 19 (9%) hybrid. 50 patients (24%) presented with GIH, 44 (21%) within 30 days of OR/ER, at a median time of 6.5 days postoperatively. CS-GIH occurred in 37 patients (18%), which led to death in two patients (1%), prolongation of ICU course or transfer to ICU in 28 patients (14%), RBC transfusion in 21 (10%), diagnostic/therapeutic endoscopy/colonoscopy in 18 (9%), and hospital readmission in 14 patients (7%). Endoscopy/Colonoscopy was diagnostic in 9 patients (ulcer in five patients, angioectasia in two, and anastomotic bleeding or colonic necrosis in one each), therapeutic in four, and identifying one patient with diffuse bleeding requiring operative intervention. Factors associated with increased risk of CS-GIH were bowel resection during index hospitalization (OR 11.29, p < 0.001), acute presentation (OR 5.42, p < 0.001), atrial fibrillation (OR 3.01, p = 0.004), first-time initiation of antiplatelet therapy (OR 2.61, p = 0.01), and treatment with stenting (2.31, p = 0.03 OR) (Table I).

Conclusion: Patients undergoing mesenteric revascularization are at high risk for postoperative gastrointestinal hemorrhage, which increases morbidity and hospitalization resources in nearly 20% of patients. Specific patient groups are at high risk for CS-GI hemorrhage. Post-operative care pathways should consider these risk factors to reduce CS-GIH after mesenteric revascularization to improve outcomes.

目的:肠系膜血管重建术后胃肠道出血(GIH)在开放手术(OR)或血管内手术(ER)中均有临床观察,但未见报道。本研究旨在评估肠系膜血管重建术患者 GIH 的发生率和预测因素:单中心回顾性研究 2009-2019 年间接受开放或血管内肠系膜血管重建术的连续患者。排除非闭塞性肠系膜缺血、术中或围手术期24小时内死亡或无术后随访的患者。主要终点是术后30天和60天内临床显著性肠系膜缺血的发生率和预测因素。如果患者需要输注红细胞、再次入院、升级到重症监护、长期停止抗凝或需要进行内镜/结肠镜检查,则定义为有临床意义的 GIH(CS-GIH):共有 260 名肠系膜缺血患者接受了手术室/手术室手术。205名患者符合纳入标准(139名女性[68%],平均年龄69.9岁[18-92岁])。128名患者(62%)表现为慢性肠系膜缺血,45名患者(22%)表现为急性肠系膜缺血,32名患者(16%)表现为急性肠系膜缺血。93人(45%)接受了手术室手术,93人(45%)接受了急诊室手术,19人(9%)接受了混合手术。50名患者(24%)出现GIH,其中44名(21%)在手术/急诊室手术后30天内出现,术后中位时间为6.5天。37名患者(18%)出现CS-GIH,导致2名患者(1%)死亡,28名患者(14%)重症监护室病程延长或转入重症监护室,21名患者(10%)输注红细胞,18名患者(9%)接受内镜/结肠镜诊断/治疗,14名患者(7%)再次入院。内镜/结肠镜检查对 9 名患者进行了诊断(5 名患者为溃疡,2 名患者为血管扩张,1 名患者为吻合口出血或结肠坏死),对 4 名患者进行了治疗,并发现 1 名患者有弥漫性出血,需要进行手术干预。与CS-GIH风险增加相关的因素有:住院期间肠切除术(OR 11.29,P<0.001)、急性发病(OR 5.42,P<0.001)、心房颤动(OR 3.01,P=0.004)、首次开始抗血小板治疗(OR 2.61,P=0.01)和支架治疗(OR 2.31,P=0.03)(表I):结论:接受肠系膜血管重建术的患者术后发生胃肠道出血的风险很高,近20%的患者会因此增加发病率和住院资源。特定患者群体是 CS-GI 大出血的高危人群。术后护理路径应考虑这些风险因素,以减少肠系膜血管重建术后 CS-GIH 的发生,从而改善预后。
{"title":"Incidence and Predictors of Gastrointestinal Hemorrhage following Mesenteric Revascularization.","authors":"Armin Farazdaghi, Diego V S Rodrigues, Claire Cassianni, Jill J Colglazier, Gustavo S Oderich, Manju Kalra, Fahad Shuja, Melinda Schaller, Todd Rasmussen, Randall R DeMartino, Bernardo C Mendes","doi":"10.1016/j.jvs.2024.11.006","DOIUrl":"https://doi.org/10.1016/j.jvs.2024.11.006","url":null,"abstract":"<p><strong>Objectives: </strong>Post-operative gastrointestinal hemorrhage (GIH) following mesenteric revascularization when performed either open (OR) or endovascularly (ER) has been clinically observed but not reported. The aim of the study is to assess the incidence and predictors of GIH in patients undergoing mesenteric revascularization.</p><p><strong>Methods: </strong>Single-center retrospective review of consecutive patients treated with open or endovascular mesenteric revascularization from 2009-2019. Patients with non-occlusive mesenteric ischemia, intraoperative or perioperative death within 24 hours, or no post-operative follow-up were excluded. Primary endpoints were incidence and predictors of clinically significant GIH within 30- and 60 days postoperatively. Clinically significant GIH (CS-GIH) was defined if patients required RBC transfusion, hospital re-admission, escalation to intensive care, prolonged discontinuation of anticoagulation, or need for endoscopy/colonoscopy.</p><p><strong>Results: </strong>A total of 260 patients presented with mesenteric ischemia and underwent OR/ER. 205 patients met inclusion criteria (139 female [68%], mean age of 69.9 years [range 18-92 years]). Presentation was chronic mesenteric ischemia in 128 patients (62%), acute-on-chronic in 45 (22%) and acute in 32 (16%). 93 (45%) underwent OR, 93 (45%) ER, and 19 (9%) hybrid. 50 patients (24%) presented with GIH, 44 (21%) within 30 days of OR/ER, at a median time of 6.5 days postoperatively. CS-GIH occurred in 37 patients (18%), which led to death in two patients (1%), prolongation of ICU course or transfer to ICU in 28 patients (14%), RBC transfusion in 21 (10%), diagnostic/therapeutic endoscopy/colonoscopy in 18 (9%), and hospital readmission in 14 patients (7%). Endoscopy/Colonoscopy was diagnostic in 9 patients (ulcer in five patients, angioectasia in two, and anastomotic bleeding or colonic necrosis in one each), therapeutic in four, and identifying one patient with diffuse bleeding requiring operative intervention. Factors associated with increased risk of CS-GIH were bowel resection during index hospitalization (OR 11.29, p < 0.001), acute presentation (OR 5.42, p < 0.001), atrial fibrillation (OR 3.01, p = 0.004), first-time initiation of antiplatelet therapy (OR 2.61, p = 0.01), and treatment with stenting (2.31, p = 0.03 OR) (Table I).</p><p><strong>Conclusion: </strong>Patients undergoing mesenteric revascularization are at high risk for postoperative gastrointestinal hemorrhage, which increases morbidity and hospitalization resources in nearly 20% of patients. Specific patient groups are at high risk for CS-GI hemorrhage. Post-operative care pathways should consider these risk factors to reduce CS-GIH after mesenteric revascularization to improve outcomes.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic review of therapies for aortobronchial fistulae. 主动脉支气管瘘治疗方法的系统回顾。
IF 3.9 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-18 DOI: 10.1016/j.jvs.2021.08.112
Christiana Anastasiadou, George Trellopoulos, Stavroula Kastora, Ioannis Kakisis, Anastasios Papapetrou, George Galyfos, George Geroulakos, Angelos Megalopoulos

Objective: The aim of the study was to summarize epidemiologic data about aortobronchial fistulas and compare outcomes (mortality, recurrence, re-operation) of open, staged, and endovascular repair of aortobronchial fistula.

Methods: A systematic literature review was conducted to identify eligible studies published between January of 1999 and December of 2019. The Cochrane Library, PubMed and Scopus databases were used as search engines. Eligible studies included articles reporting postoperative outcomes (death/follow-up). Literature review revealed only case reports and small case series and thus, only descriptive data with data heterogeneity was available. The corresponding authors were contacted to provide additional information or outcome updates (recurrence/reoperation/death).

Results: Overall, 214 patients (90 studies) underwent 271 procedures (including re-do procedures and staged procedures). Most of the patients were treated by endovascular means (72.42%). Open surgical repair was performed in 21.96% and staged procedures in 5.6%. Aortobronchial fistulae located most often in the descending thoracic aorta (Zone 3,4) (64,6%) and in Zone 2 (23,8%). Fourteen percent of aortobronchial fistulae developed after thoracic endovascular aneurysm repair. Recurrence or infection occurred in 20% (43 patients). Recurrences were at some extend associated with the presence of endoleak. Long-term antibiotic administration (>1 month) was instituted in 63 patients (29.4%), whilst 90 patients (42%) did not receive antibiotics beyond hospitalization. From the remaining 61, 3 received life-long antibiotics and for 58 patients data were not available. Considering outcomes, mean follow-up was 25.1 months (0-188 months) and not significantly different among treatments.

Limitations: Literature review has revealed only case reports and small case series and thus, only descriptive data were available. Randomized controlled trials are not available due to the rarity of the disease which significantly decreases the power of the present study. Also, this study reflects significant data heterogeneity due to the nature of the analyzed manuscripts and would benefit from large patient cohort studies which till today have not been conducted.

Conclusion: Aortobronchial fistula is a complex disease. Endoleaks may be involved in the development and in recurrence process and they should not be disregarded. Considering major outcomes (length of follow-up), the available treating strategies are equal and thus, surgeons should feel confident to apply the treatment of their choice, taking in mind their experience, patient's age, and clinical condition.

研究目的该研究旨在总结主动脉支气管瘘的流行病学数据,并比较主动脉支气管瘘开放、分期和血管内修复的结果(死亡率、复发率、再次手术率):进行了系统性文献回顾,以确定 1999 年 1 月至 2019 年 12 月间发表的符合条件的研究。研究使用 Cochrane Library、PubMed 和 Scopus 数据库作为搜索引擎。符合条件的研究包括报告术后结果(死亡/随访)的文章。文献综述仅显示了病例报告和小型病例系列,因此仅提供了具有数据异质性的描述性数据。我们联系了相应的作者以提供更多信息或结果更新(复发/手术/死亡):共有 214 名患者(90 项研究)接受了 271 例手术(包括重做手术和分期手术)。大多数患者接受了血管内治疗(72.42%)。21.96%的患者接受了开放手术修复,5.6%的患者接受了分期手术。主动脉支气管瘘最常位于降胸主动脉(3、4区)(64.6%)和2区(23.8%)。14%的主动脉支气管瘘是在胸腔内血管瘤修复术后形成的。复发或感染发生率为 20%(43 名患者)。复发在一定程度上与内漏的存在有关。63名患者(29.4%)接受了长期抗生素治疗(>1个月),90名患者(42%)住院后未接受抗生素治疗。其余 61 名患者中,3 人终身使用抗生素,58 人的数据不详。就结果而言,平均随访时间为 25.1 个月(0-188 个月),不同治疗方法之间没有明显差异:局限性:文献综述中仅有病例报告和小型病例系列,因此只能提供描述性数据。由于该疾病的罕见性,随机对照试验不可用,这大大降低了本研究的有效性。此外,由于所分析手稿的性质,本研究反映出数据的显著异质性,大型患者队列研究将使本研究受益匪浅,而迄今为止尚未开展过此类研究:结论:主动脉支气管瘘是一种复杂的疾病。结论:主动脉支气管瘘是一种复杂的疾病,内漏可能与疾病的发展和复发过程有关,不应被忽视。考虑到主要结果(随访时间),现有的治疗策略是平等的,因此,外科医生应该有信心根据自己的经验、患者年龄和临床状况选择治疗方法。
{"title":"A systematic review of therapies for aortobronchial fistulae.","authors":"Christiana Anastasiadou, George Trellopoulos, Stavroula Kastora, Ioannis Kakisis, Anastasios Papapetrou, George Galyfos, George Geroulakos, Angelos Megalopoulos","doi":"10.1016/j.jvs.2021.08.112","DOIUrl":"https://doi.org/10.1016/j.jvs.2021.08.112","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to summarize epidemiologic data about aortobronchial fistulas and compare outcomes (mortality, recurrence, re-operation) of open, staged, and endovascular repair of aortobronchial fistula.</p><p><strong>Methods: </strong>A systematic literature review was conducted to identify eligible studies published between January of 1999 and December of 2019. The Cochrane Library, PubMed and Scopus databases were used as search engines. Eligible studies included articles reporting postoperative outcomes (death/follow-up). Literature review revealed only case reports and small case series and thus, only descriptive data with data heterogeneity was available. The corresponding authors were contacted to provide additional information or outcome updates (recurrence/reoperation/death).</p><p><strong>Results: </strong>Overall, 214 patients (90 studies) underwent 271 procedures (including re-do procedures and staged procedures). Most of the patients were treated by endovascular means (72.42%). Open surgical repair was performed in 21.96% and staged procedures in 5.6%. Aortobronchial fistulae located most often in the descending thoracic aorta (Zone 3,4) (64,6%) and in Zone 2 (23,8%). Fourteen percent of aortobronchial fistulae developed after thoracic endovascular aneurysm repair. Recurrence or infection occurred in 20% (43 patients). Recurrences were at some extend associated with the presence of endoleak. Long-term antibiotic administration (>1 month) was instituted in 63 patients (29.4%), whilst 90 patients (42%) did not receive antibiotics beyond hospitalization. From the remaining 61, 3 received life-long antibiotics and for 58 patients data were not available. Considering outcomes, mean follow-up was 25.1 months (0-188 months) and not significantly different among treatments.</p><p><strong>Limitations: </strong>Literature review has revealed only case reports and small case series and thus, only descriptive data were available. Randomized controlled trials are not available due to the rarity of the disease which significantly decreases the power of the present study. Also, this study reflects significant data heterogeneity due to the nature of the analyzed manuscripts and would benefit from large patient cohort studies which till today have not been conducted.</p><p><strong>Conclusion: </strong>Aortobronchial fistula is a complex disease. Endoleaks may be involved in the development and in recurrence process and they should not be disregarded. Considering major outcomes (length of follow-up), the available treating strategies are equal and thus, surgeons should feel confident to apply the treatment of their choice, taking in mind their experience, patient's age, and clinical condition.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preoperative Radiological Features in Predicting Complications of Carotid Body Tumor Resection. 预测颈动脉体瘤切除术并发症的术前放射学特征
IF 3.9 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-16 DOI: 10.1016/j.jvs.2024.11.008
Tariq Alanezi, Faris Alomran, Samer Koussayer, Omer Abdulrahim, Mohammed Dahman, Eyas Alsuhaibani, Riyadh Alokaili, Mohammed Al-Omran

Background: Carotid body tumors (CBTs) are rare neoplasms that pose significant surgical challenges. This study aims to evaluate the predictive utility of preoperative radiological characteristics on postoperative complications in patients undergoing CBT resection at a tertiary care center.

Methods: A retrospective analysis was conducted on 106 patients who underwent CBT resection between 2003 and 2023. Patient demographics, tumor characteristics, and operative details were collected. The primary outcomes were an estimated blood loss (EBL) >250 mL and cranial nerve (CN) injury. Logistic regression models were used to identify significant preoperative radiological predictors, including Shamblin grade, Peking Union Medical College Hospital (PUMCH) grade, tumor distance to the base of the skull (DTBOS), and tumor volume.

Results: One hundred and six patients were included. Higher Shamblin and PUMCH grades were significantly associated with increased EBL and CN injury. Specifically, the Shamblin grade alone predicted an EBL >250 mL with a McFadden R2 value of 0.14, which slightly decreased to 0.13 when DTBOS and tumor volume were added. For CN injury, the Shamblin grade alone had an R2 of 0.16, which significantly improved to 0.27 with the addition of DTBOS and further to 0.29 with tumor volume. The PUMCH grade alone predicted an EBL >250 mL with an R2 value of 0.08, which did not significantly change with the addition of DTBOS and tumor volume. For CN injury, the PUMCH grade alone had an R2 of 0.14, improving to 0.21 with DTBOS and to 0.22 with tumor volume. Furthermore, a 1-cm decrease in DTBOS significantly increased the odds of requiring a blood transfusion (OR = 2.26, 95% CI: 1.28-4.01, p=0.0051) and the risk of CN injury (OR = 3.65, 95% CI: 1.98-6.73, p<0.0001).

Conclusion: This study identified novel preoperative radiological predictors that enhance the predictive accuracy of standard classification systems, offering valuable insights for preoperative planning. While the Shamblin and PUMCH classifications are useful tools on their own, our findings demonstrate that incorporating additional radiological features, such as DTBOS and tumor volume, can substantially increase their predictive utility. Surgeons are encouraged to incorporate multiple preoperative radiological variables alongside traditional classification systems to better assess the risk of postoperative complications. Further research with larger, multi-institutional cohorts are necessary to validate these findings and refine predictive models.

背景:颈动脉体肿瘤(CBT)是一种罕见肿瘤,给外科手术带来了巨大挑战。本研究旨在评估一家三级医疗中心接受CBT切除术的患者术前放射学特征对术后并发症的预测作用:方法:对 2003 年至 2023 年期间接受 CBT 切除术的 106 例患者进行回顾性分析。收集了患者的人口统计学特征、肿瘤特征和手术细节。主要结果是估计失血量(EBL)>250 毫升和颅神经(CN)损伤。采用逻辑回归模型确定重要的术前放射学预测因素,包括Shamblin分级、北京协和医院(PUMCH)分级、肿瘤到颅底的距离(DTBOS)和肿瘤体积:结果:共纳入 106 名患者。Shamblin和PUMCH分级越高,EBL和CN损伤越严重。具体来说,仅凭香卜林分级就能预测 EBL >250 mL,其 McFadden R2 值为 0.14,加上 DTBOS 和肿瘤体积后,该值略微下降至 0.13。对于 CN 损伤,单独使用 Shamblin 分级的 R2 值为 0.16,加入 DTBOS 后,R2 值显著提高到 0.27,加入肿瘤体积后,R2 值进一步提高到 0.29。单用 PUMCH 分级预测 EBL >250 mL 的 R2 值为 0.08,在加入 DTBOS 和肿瘤体积后没有明显变化。对于 CN 损伤,单独使用 PUMCH 分级的 R2 值为 0.14,加入 DTBOS 后 R2 值提高到 0.21,加入肿瘤体积后 R2 值提高到 0.22。此外,DTBOS 下降 1 厘米会显著增加需要输血的几率(OR = 2.26,95% CI:1.28-4.01,p=0.0051)和 CN 损伤的风险(OR = 3.65,95% CI:1.98-6.73,p 结论:本研究发现了新的术前放射学预测指标,这些指标提高了标准分类系统的预测准确性,为术前规划提供了宝贵的见解。虽然 Shamblin 和 PUMCH 分类本身是很有用的工具,但我们的研究结果表明,结合其他放射学特征(如 DTBOS 和肿瘤体积)可大大提高其预测效用。我们鼓励外科医生将多种术前放射学变量与传统分类系统结合起来,以更好地评估术后并发症的风险。为了验证这些发现并完善预测模型,有必要对更大规模的多机构队列进行进一步研究。
{"title":"Preoperative Radiological Features in Predicting Complications of Carotid Body Tumor Resection.","authors":"Tariq Alanezi, Faris Alomran, Samer Koussayer, Omer Abdulrahim, Mohammed Dahman, Eyas Alsuhaibani, Riyadh Alokaili, Mohammed Al-Omran","doi":"10.1016/j.jvs.2024.11.008","DOIUrl":"10.1016/j.jvs.2024.11.008","url":null,"abstract":"<p><strong>Background: </strong>Carotid body tumors (CBTs) are rare neoplasms that pose significant surgical challenges. This study aims to evaluate the predictive utility of preoperative radiological characteristics on postoperative complications in patients undergoing CBT resection at a tertiary care center.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 106 patients who underwent CBT resection between 2003 and 2023. Patient demographics, tumor characteristics, and operative details were collected. The primary outcomes were an estimated blood loss (EBL) >250 mL and cranial nerve (CN) injury. Logistic regression models were used to identify significant preoperative radiological predictors, including Shamblin grade, Peking Union Medical College Hospital (PUMCH) grade, tumor distance to the base of the skull (DTBOS), and tumor volume.</p><p><strong>Results: </strong>One hundred and six patients were included. Higher Shamblin and PUMCH grades were significantly associated with increased EBL and CN injury. Specifically, the Shamblin grade alone predicted an EBL >250 mL with a McFadden R<sup>2</sup> value of 0.14, which slightly decreased to 0.13 when DTBOS and tumor volume were added. For CN injury, the Shamblin grade alone had an R<sup>2</sup> of 0.16, which significantly improved to 0.27 with the addition of DTBOS and further to 0.29 with tumor volume. The PUMCH grade alone predicted an EBL >250 mL with an R<sup>2</sup> value of 0.08, which did not significantly change with the addition of DTBOS and tumor volume. For CN injury, the PUMCH grade alone had an R<sup>2</sup> of 0.14, improving to 0.21 with DTBOS and to 0.22 with tumor volume. Furthermore, a 1-cm decrease in DTBOS significantly increased the odds of requiring a blood transfusion (OR = 2.26, 95% CI: 1.28-4.01, p=0.0051) and the risk of CN injury (OR = 3.65, 95% CI: 1.98-6.73, p<0.0001).</p><p><strong>Conclusion: </strong>This study identified novel preoperative radiological predictors that enhance the predictive accuracy of standard classification systems, offering valuable insights for preoperative planning. While the Shamblin and PUMCH classifications are useful tools on their own, our findings demonstrate that incorporating additional radiological features, such as DTBOS and tumor volume, can substantially increase their predictive utility. Surgeons are encouraged to incorporate multiple preoperative radiological variables alongside traditional classification systems to better assess the risk of postoperative complications. Further research with larger, multi-institutional cohorts are necessary to validate these findings and refine predictive models.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac Remodeling and Antihypertensive Medication Changes After Thoracic Endovascular Aortic Repair vs Open Surgical Repair. 胸腔内血管主动脉修复术与开放手术修复术后的心脏重塑和降压药物变化
IF 3.9 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-16 DOI: 10.1016/j.jvs.2024.11.007
Karen Yuan, Vamsi K Potluri, Akshita Gorantla, Nabeeha Khan, Irene Helenowski, Michael C Soult, Jeffrey Schwartz, Carlos F Bechara

Objective: Cardiovascular complications remain one of the major all-cause mortalities among patients who receive either thoracic endovascular aortic repair (TEVAR) or open surgical repair (OSR). Increased aortic stiffness after endograft deployment has been shown to induce left ventricular hypertrophy, diastolic dysfunction, and reduced coronary flow reserve. However, there is limited data on the hemodynamic effects after OR. The purpose of this study is to compare the cardiovascular and hemodynamic changes after TEVAR and OR.

Methods: A retrospective analysis of 100 patients with thoracic aortic aneurysm or dissection who underwent open (n=50) or endovascular repair (n=50) was conducted. Information on demographics, medical and surgical history, and clinical outcomes were retrieved. Transthoracic echocardiographic (TTE) imaging results were collected to assess cardiac function. Changes to antihypertensive medication dosage and number were used as surrogate markers for hemodynamic changes and aortic stiffness.

Results: No statistically significant differences were observed in antihypertensive medication number or dosage between the TEVAR and OSR group at 12 months, 24 months, and 36 months post-surgery. When adjusting for patient demographic factors of age, sex, and BSA in a multivariable generalized estimating equation model, patients who underwent TEVAR had a higher likelihood of receiving more antihypertensive medications (IRR = 1.131; P = .044). Patient characteristics such as BSA (IRR = 1.266; P = .001), HTN (IRR = 2.070; P ≤ .001), DM (IRR = 1.474; P ≤ .001), ESRD (IRR = 1.304; P = .011) were also associated with a higher number of antihypertensive medications. A significant increase in beta-blockers (P ≤ .001) and diuretics (P = .046) intake was observed post-TEVAR and post-OR. No significant differences in left ventricular ejection fraction and left ventricular hypertrophy were observed between the two groups.

Conclusions: We observed a greater likelihood of antihypertensive medications escalation following TEVAR, suggesting an increase in aortic stiffness post-operatively. No significant differences in cardiac remodeling were observed between the two groups. Our findings emphasize the need for an improved post-operative cardiac surveillance program in patients undergoing both TEVAR and OSR. Furthermore, additional innovation is needed to create aortic grafts that are more compatible with the native aorta in order to reduce long-term cardiovascular complications.

目的:在接受胸腔内血管主动脉修复术(TEVAR)或开放手术修复术(OSR)的患者中,心血管并发症仍是主要的全因死亡率之一。研究表明,主动脉内移植物植入后主动脉僵硬度增加会导致左心室肥厚、舒张功能障碍和冠状动脉血流储备减少。然而,关于手术后血流动力学影响的数据却很有限。本研究旨在比较 TEVAR 和手术后的心血管和血流动力学变化:方法:对100例胸主动脉瘤或夹层患者进行回顾性分析,这些患者接受了开胸手术(50例)或血管内修复术(50例)。研究人员检索了有关人口统计学、病史、手术史和临床结果的信息。收集了经胸超声心动图(TTE)成像结果,以评估心脏功能。降压药物剂量和数量的变化被用作血流动力学变化和主动脉僵化的替代指标:结果:在手术后12个月、24个月和36个月,TEVAR组和OSR组的降压药物数量和用量在统计学上没有明显差异。在多变量广义估计方程模型中对患者的年龄、性别和 BSA 等人口统计学因素进行调整后,接受 TEVAR 的患者接受更多降压药物治疗的可能性更高(IRR = 1.131;P = .044)。BSA(IRR = 1.266;P = .001)、HTN(IRR = 2.070;P ≤ .001)、DM(IRR = 1.474;P ≤ .001)、ESRD(IRR = 1.304;P = .011)等患者特征也与较多的降压药物相关。TEVAR术后和OR术后观察到β-受体阻滞剂(P≤ .001)和利尿剂(P = .046)的摄入量明显增加。两组患者的左心室射血分数和左心室肥厚程度无明显差异:结论:我们观察到,TEVAR术后降压药升级的可能性更大,这表明术后主动脉僵硬度增加。两组患者的心脏重塑情况无明显差异。我们的研究结果表明,对于同时接受 TEVAR 和 OSR 的患者,需要改进术后心脏监测计划。此外,为了减少长期的心血管并发症,还需要进行更多的创新,以制造出与原生主动脉更相容的主动脉移植物。
{"title":"Cardiac Remodeling and Antihypertensive Medication Changes After Thoracic Endovascular Aortic Repair vs Open Surgical Repair.","authors":"Karen Yuan, Vamsi K Potluri, Akshita Gorantla, Nabeeha Khan, Irene Helenowski, Michael C Soult, Jeffrey Schwartz, Carlos F Bechara","doi":"10.1016/j.jvs.2024.11.007","DOIUrl":"10.1016/j.jvs.2024.11.007","url":null,"abstract":"<p><strong>Objective: </strong>Cardiovascular complications remain one of the major all-cause mortalities among patients who receive either thoracic endovascular aortic repair (TEVAR) or open surgical repair (OSR). Increased aortic stiffness after endograft deployment has been shown to induce left ventricular hypertrophy, diastolic dysfunction, and reduced coronary flow reserve. However, there is limited data on the hemodynamic effects after OR. The purpose of this study is to compare the cardiovascular and hemodynamic changes after TEVAR and OR.</p><p><strong>Methods: </strong>A retrospective analysis of 100 patients with thoracic aortic aneurysm or dissection who underwent open (n=50) or endovascular repair (n=50) was conducted. Information on demographics, medical and surgical history, and clinical outcomes were retrieved. Transthoracic echocardiographic (TTE) imaging results were collected to assess cardiac function. Changes to antihypertensive medication dosage and number were used as surrogate markers for hemodynamic changes and aortic stiffness.</p><p><strong>Results: </strong>No statistically significant differences were observed in antihypertensive medication number or dosage between the TEVAR and OSR group at 12 months, 24 months, and 36 months post-surgery. When adjusting for patient demographic factors of age, sex, and BSA in a multivariable generalized estimating equation model, patients who underwent TEVAR had a higher likelihood of receiving more antihypertensive medications (IRR = 1.131; P = .044). Patient characteristics such as BSA (IRR = 1.266; P = .001), HTN (IRR = 2.070; P ≤ .001), DM (IRR = 1.474; P ≤ .001), ESRD (IRR = 1.304; P = .011) were also associated with a higher number of antihypertensive medications. A significant increase in beta-blockers (P ≤ .001) and diuretics (P = .046) intake was observed post-TEVAR and post-OR. No significant differences in left ventricular ejection fraction and left ventricular hypertrophy were observed between the two groups.</p><p><strong>Conclusions: </strong>We observed a greater likelihood of antihypertensive medications escalation following TEVAR, suggesting an increase in aortic stiffness post-operatively. No significant differences in cardiac remodeling were observed between the two groups. Our findings emphasize the need for an improved post-operative cardiac surveillance program in patients undergoing both TEVAR and OSR. Furthermore, additional innovation is needed to create aortic grafts that are more compatible with the native aorta in order to reduce long-term cardiovascular complications.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anesthesia choice for frail patients undergoing endovascular repair of non-ruptured infrarenal abdominal aortic aneurysms. 接受非破裂的肾下腹主动脉瘤血管内修复术的体弱患者的麻醉选择。
IF 3.9 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-11 DOI: 10.1016/j.jvs.2024.10.077
Renxi Li, Anton Sidawy, Bao-Ngoc Nguyen

Background: While general anesthesia is the predominant choice in endovascular aneurysm repair (EVAR), recent studies have suggested that locoregional anesthesia could be a viable alternative for suitable patients. Frailty has been identified as an independent predictor of elevated mortality and morbidity in EVAR. However, the choice of anesthesia in frail patients undergoing EVAR has not been explored.

Methods: This study aimed to compare the 30-day outcomes of non-emergent intact infrarenal EVAR in frail patients receiving either locoregional or general anesthesia. Patients who underwent infrarenal EVAR were identified in ACS-NSQIP database from 2012-2022. Frail patients were selected by 5-item Modified Frailty Index (mFI-5)≥2. Exclusion criteria included age<18 years, ruptured abdominal aortic aneurysm (AAA), emergency, and acute intraoperative conversion to open. A 1:1 propensity-score matching was used to match demographics, baseline characteristics, aneurysm diameter, distal aneurysm extent, and concomitant procedures between patients under locoregional and general anesthesia. Thirty-day postoperative outcomes were evaluated.

Results: Among 16,438 patients who underwent EVAR, 4812 (29.27%) were frail. Among the frail patients, 483 (10.04%) were under locoregional anesthesia while 4,329 (89.96%) were under general anesthesia. After propensity-score matching, patients under locoregional or general anesthesia had comparable 30-day mortality (2.07% vs 2.48%, p=0.83) or any complications.

Conclusion: Locoregional and general anesthesia were found to have comparable postoperative outcomes in frail patients undergoing EVAR unruptured AAA, which did not align with the suggestion that locoregional anesthesia might be more advantageous in frail patients. While the patient's preferences should be considered, the choice of anesthesia should still be individualized to take into account the patient's age, comorbidities, AAA anatomy and the complexity of the case, as well as previous surgical and anesthesia experiences.

背景:虽然全身麻醉是血管内动脉瘤修补术(EVAR)的主要选择,但最近的研究表明,对于合适的患者来说,局部麻醉可能是一种可行的替代方法。体弱已被确定为 EVAR 死亡率和发病率升高的独立预测因素。然而,对接受 EVAR 的体弱患者选择何种麻醉方式尚未进行探讨:本研究旨在比较接受局部麻醉或全身麻醉的体弱患者接受非急诊完整髂腹下 EVAR 术后 30 天的预后。2012-2022年期间,在ACS-NSQIP数据库中确定了接受肾下EVAR的患者。根据5项改良虚弱指数(mFI-5)≥2筛选出虚弱患者。排除标准包括年龄结果:在接受EVAR手术的16438名患者中,有4812名(29.27%)是体弱患者。在体弱患者中,483人(10.04%)进行了局部麻醉,4329人(89.96%)进行了全身麻醉。经过倾向分数匹配后,接受局部麻醉或全身麻醉的患者的30天死亡率(2.07% vs 2.48%,P=0.83)或任何并发症的发生率相当:结论:在接受EVAR未破裂AAA手术的体弱患者中,局部麻醉和全身麻醉的术后效果相当,这与局部麻醉可能对体弱患者更有利的说法并不一致。虽然应考虑患者的偏好,但麻醉的选择仍应因人而异,考虑患者的年龄、合并症、AAA 的解剖结构、病例的复杂程度以及既往的手术和麻醉经验。
{"title":"Anesthesia choice for frail patients undergoing endovascular repair of non-ruptured infrarenal abdominal aortic aneurysms.","authors":"Renxi Li, Anton Sidawy, Bao-Ngoc Nguyen","doi":"10.1016/j.jvs.2024.10.077","DOIUrl":"https://doi.org/10.1016/j.jvs.2024.10.077","url":null,"abstract":"<p><strong>Background: </strong>While general anesthesia is the predominant choice in endovascular aneurysm repair (EVAR), recent studies have suggested that locoregional anesthesia could be a viable alternative for suitable patients. Frailty has been identified as an independent predictor of elevated mortality and morbidity in EVAR. However, the choice of anesthesia in frail patients undergoing EVAR has not been explored.</p><p><strong>Methods: </strong>This study aimed to compare the 30-day outcomes of non-emergent intact infrarenal EVAR in frail patients receiving either locoregional or general anesthesia. Patients who underwent infrarenal EVAR were identified in ACS-NSQIP database from 2012-2022. Frail patients were selected by 5-item Modified Frailty Index (mFI-5)≥2. Exclusion criteria included age<18 years, ruptured abdominal aortic aneurysm (AAA), emergency, and acute intraoperative conversion to open. A 1:1 propensity-score matching was used to match demographics, baseline characteristics, aneurysm diameter, distal aneurysm extent, and concomitant procedures between patients under locoregional and general anesthesia. Thirty-day postoperative outcomes were evaluated.</p><p><strong>Results: </strong>Among 16,438 patients who underwent EVAR, 4812 (29.27%) were frail. Among the frail patients, 483 (10.04%) were under locoregional anesthesia while 4,329 (89.96%) were under general anesthesia. After propensity-score matching, patients under locoregional or general anesthesia had comparable 30-day mortality (2.07% vs 2.48%, p=0.83) or any complications.</p><p><strong>Conclusion: </strong>Locoregional and general anesthesia were found to have comparable postoperative outcomes in frail patients undergoing EVAR unruptured AAA, which did not align with the suggestion that locoregional anesthesia might be more advantageous in frail patients. While the patient's preferences should be considered, the choice of anesthesia should still be individualized to take into account the patient's age, comorbidities, AAA anatomy and the complexity of the case, as well as previous surgical and anesthesia experiences.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thirty-Day Outcomes from the Disrupt PAD BTK II Study of the Shockwave Intravascular Lithotripsy System for Treatment of Calcified Below-the-Knee Peripheral Arterial Disease. 冲击波血管内碎石系统治疗钙化性膝以下外周动脉疾病的 Disrupt PAD BTK II 研究的 30 天结果。
IF 3.9 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-11 DOI: 10.1016/j.jvs.2024.11.003
Venita Chandra, Alexandra J Lansky, Sameh Sayfo, Nicolas W Shammas, Peter Soukas, James Park, Michael Siah, Anvar Babaev, Ryan Shields, Nick E J West, Ehrin Armstrong

Background: Below the knee (BTK) lesions may be particularly challenging to treat owing to length, diffuse disease, and extent of calcification. Landmark interventional clinical studies have not reached consensus on the optimal standard of care for BTK lesions, and many published trials excluded patients with moderate or severe lesion calcification. Calcium modification with intravascular lithotripsy (IVL) was shown to be superior to percutaneous transluminal angioplasty (PTA) in the femoropopliteal artery and successful in treating BTK lesions in pilot studies. The Disrupt BTK II study is a core-lab adjudicated, prospective, multi-center single-arm study of patients with moderate to severely calcified BTK lesions treated with the Shockwave Medical Peripheral IVL System.

Methods: Disrupt BTK II enrolled 250 subjects with calcified infrapopliteal lesions and Rutherford category 3-5 presentation from 38 sites in the United States and Europe. The primary safety endpoint was major adverse limb events (MALE) or post-operative death (POD) at 30 days, a composite of all-cause death, above-ankle amputation of the index limb, and/or major reintervention of the index limb involving an infrapopliteal artery. The primary effectiveness endpoint was procedural success, defined as ≤50% residual stenosis for all treated target lesions without serious core lab-adjudicated serious angiographic complications. The study used independent angiographic and duplex ultrasound core laboratories, and follow-up is planned through two years.

Results: A total of 305 lesions in 250 patients were treated with a procedural success of 97.9%. Mean target lesion length was 76 ± 65mm, diameter stenosis was 78 ± 18%, and 84.8% had moderate or severe calcification as assessed by an independent angiographic core lab. After IVL, residual stenosis was reduced to 29%, and to 26% after optional post-dilatation and/or stent implantation. At 30 days, there were no deaths, MALE rate was 0.8%, and mean improvement in VascuQoL scores was 4.0 ± 5.0 (P<0.0001). Of the patients with baseline wounds, 15.8% healed and 53.4% were improved at 30 days.

Conclusions: The Disrupt PAD BTK II study demonstrated that treatment with the Shockwave Medical Peripheral IVL System in patients with moderate-severe calcified lesions resulted in high procedural success, significant reduction in residual stenosis, improvements in patient QoL and wound healing, with minimal adverse events at 30-day follow-up.

背景:膝关节以下(BTK)病变因其长度、病变弥漫性和钙化程度,治疗起来尤其具有挑战性。具有里程碑意义的介入临床研究尚未就治疗膝下骨关节病变的最佳标准达成共识,许多已发表的试验将中度或重度病变钙化患者排除在外。试验研究表明,血管内碎石术(IVL)的钙化修饰效果优于股动脉经皮腔内血管成形术(PTA),并能成功治疗 BTK 病变。Disrupt BTK II 研究是一项经核心实验室评审的前瞻性多中心单臂研究,研究对象是使用冲击波医疗外周 IVL 系统治疗中度至重度钙化 BTK 病变的患者:方法:Disrupt BTK II 从美国和欧洲的 38 个研究机构招募了 250 名患有钙化下髂病变和卢瑟福 3-5 类表现的受试者。主要安全性终点是30天内肢体主要不良事件(MALE)或术后死亡(POD),即全因死亡、指数肢体踝关节以上截肢和/或涉及髂下动脉的指数肢体主要再介入。主要有效性终点是手术成功率,定义为所有治疗过的靶病变残余狭窄率≤50%,且无核心实验室判定的严重血管造影并发症。研究使用了独立的血管造影和双相超声核心实验室,计划随访两年:250名患者共治疗了305个病灶,手术成功率为97.9%。经独立血管造影核心实验室评估,平均靶病变长度为 76 ± 65 毫米,直径狭窄率为 78 ± 18%,84.8%的病变存在中度或重度钙化。IVL 术后,残余狭窄率降至 29%,可选择后扩张和/或支架植入术后,残余狭窄率降至 26%。30天后,无死亡病例,MALE率为0.8%,VascuQoL评分的平均改善幅度为4.0 ± 5.0(PC结论:Disrupt PAD BTK II 研究表明,使用冲击波医疗外周 IVL 系统治疗中重度钙化病变患者的手术成功率很高,残余狭窄显著减少,患者 QoL 和伤口愈合得到改善,30 天随访时不良事件极少。
{"title":"Thirty-Day Outcomes from the Disrupt PAD BTK II Study of the Shockwave Intravascular Lithotripsy System for Treatment of Calcified Below-the-Knee Peripheral Arterial Disease.","authors":"Venita Chandra, Alexandra J Lansky, Sameh Sayfo, Nicolas W Shammas, Peter Soukas, James Park, Michael Siah, Anvar Babaev, Ryan Shields, Nick E J West, Ehrin Armstrong","doi":"10.1016/j.jvs.2024.11.003","DOIUrl":"https://doi.org/10.1016/j.jvs.2024.11.003","url":null,"abstract":"<p><strong>Background: </strong>Below the knee (BTK) lesions may be particularly challenging to treat owing to length, diffuse disease, and extent of calcification. Landmark interventional clinical studies have not reached consensus on the optimal standard of care for BTK lesions, and many published trials excluded patients with moderate or severe lesion calcification. Calcium modification with intravascular lithotripsy (IVL) was shown to be superior to percutaneous transluminal angioplasty (PTA) in the femoropopliteal artery and successful in treating BTK lesions in pilot studies. The Disrupt BTK II study is a core-lab adjudicated, prospective, multi-center single-arm study of patients with moderate to severely calcified BTK lesions treated with the Shockwave Medical Peripheral IVL System.</p><p><strong>Methods: </strong>Disrupt BTK II enrolled 250 subjects with calcified infrapopliteal lesions and Rutherford category 3-5 presentation from 38 sites in the United States and Europe. The primary safety endpoint was major adverse limb events (MALE) or post-operative death (POD) at 30 days, a composite of all-cause death, above-ankle amputation of the index limb, and/or major reintervention of the index limb involving an infrapopliteal artery. The primary effectiveness endpoint was procedural success, defined as ≤50% residual stenosis for all treated target lesions without serious core lab-adjudicated serious angiographic complications. The study used independent angiographic and duplex ultrasound core laboratories, and follow-up is planned through two years.</p><p><strong>Results: </strong>A total of 305 lesions in 250 patients were treated with a procedural success of 97.9%. Mean target lesion length was 76 ± 65mm, diameter stenosis was 78 ± 18%, and 84.8% had moderate or severe calcification as assessed by an independent angiographic core lab. After IVL, residual stenosis was reduced to 29%, and to 26% after optional post-dilatation and/or stent implantation. At 30 days, there were no deaths, MALE rate was 0.8%, and mean improvement in VascuQoL scores was 4.0 ± 5.0 (P<0.0001). Of the patients with baseline wounds, 15.8% healed and 53.4% were improved at 30 days.</p><p><strong>Conclusions: </strong>The Disrupt PAD BTK II study demonstrated that treatment with the Shockwave Medical Peripheral IVL System in patients with moderate-severe calcified lesions resulted in high procedural success, significant reduction in residual stenosis, improvements in patient QoL and wound healing, with minimal adverse events at 30-day follow-up.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact Of Preoperative Risk Factors On 5-year Survival After Fenestrated/Branched Endovascular Aortic Repair. 术前风险因素对血管内主动脉修补术后 5 年生存率的影响
IF 3.9 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-11 DOI: 10.1016/j.jvs.2024.11.002
Vivian Carla Gomes, F Ezequiel Parodi, Sydney E Browder, Fernando Motta, Priya Vasan, Dichen Sun, William A Marston, Luigi Pascarella, Katharine L McGinigle, Jacob C Wood, Mark A Farber

Objectives: To investigate which preoperative factors most impact the 5-year survival of patients undergoing fenestrated/branched endovascular aortic repair (F/BEVAR) and to identify modifiable elements that, if time allows, should be actively managed and adequately controlled preoperatively.

Methods: Patients treated for aortic aneurysms with complex anatomy using either a patient-specific company manufactured or an off-the-shelf F/BEVAR devices were included. The exposure of interest was aneurysm type (group I: types I-III thoracoabdominal aneurysms (TAAA) vs group II: type IV TAAA vs group III: juxtarenal or suprarenal aneurysms) and the primary outcome was 5-year risk of all-cause mortality. Generalized linear models were used to estimate each group's crude 5-year risk of death and the 5-year risk of death across groups. Each preoperative factor was added to the model individually and a change in estimate was calculated between the new risks and the crude risk. Preoperative factors with a change of estimate of ≥10% were utilized to create an inverse probability of treatment weights for multivariable analysis.

Results: Results: 408 F/BEVAR patients were included, who were 71.6% male (mean age: 72.0±7.9 years). Eleven of the 22 preoperative factors analyzed had a change in estimate ≥10%. The greatest changes in estimates were observed for history of congestive heart failure (CHF), arrhythmia, overweight, obesity, COPD. Almost 60% of patients with CHF in group I died within 5 years. Current smoking or overweight at the time of F/BEVAR increases the 5-year risk of death more significantly than having a history of myocardial infarction. After adjustment, patients in group I had a significantly higher risk of 5-year all-cause mortality compared to those in group III (log-rank p-value=0.0082).

Conclusions: The present findings suggest that cardiac arrhythmias, CHF, overweight, obesity, COPD, and aneurysm diameter above 7 cm are the most relevant preoperative elements that impact the 5-year survival post F/BEVAR. More specifically, CHF and arrhythmias should be used to alter patient selection and identify those individuals more likely to benefit from repair. Moreover, modifiable risk factors such as weight loss and smoking cessation during the surveillance period before the F/BEVAR procedure, might improve survival in this population. Considering that preoperatively, many patients are periodically evaluated by a vascular surgery team until the aneurysm diameter meets criteria for repair, a multidisciplinary approach that could address these modifiable risk factors might be an impactful strategy.

目的研究哪些术前因素对接受主动脉腔内修复术(F/BEVAR)的患者的5年存活率影响最大,并确定在时间允许的情况下应积极管理和充分控制的术前可改变因素:方法:纳入使用患者特制的公司生产或现成的 F/BEVAR 装置治疗解剖结构复杂的主动脉瘤的患者。动脉瘤类型(I组:I-III型胸腹主动脉瘤(TAAA) vs II组:IV型TAAA vs III组:并子或肾上动脉瘤)和5年全因死亡风险是主要研究结果。采用广义线性模型估算各组的粗略 5 年死亡风险和跨组 5 年死亡风险。每个术前因素都被单独添加到模型中,并计算新风险与粗风险之间的估计值变化。利用估计值变化≥10%的术前因素创建治疗逆概率权重,进行多变量分析:结果:结果:共纳入 408 例 F/BEVAR 患者,其中 71.6% 为男性(平均年龄:72.0±7.9 岁)。在分析的 22 个术前因素中,有 11 个因素的估计值变化≥10%。充血性心力衰竭(CHF)病史、心律失常、超重、肥胖、慢性阻塞性肺病的估计值变化最大。第一组近 60% 的充血性心力衰竭患者在 5 年内死亡。与心肌梗死病史相比,F/BEVAR术时吸烟或超重会更显著地增加5年死亡风险。经调整后,I组患者的5年全因死亡风险明显高于III组患者(对数秩p值=0.0082):本研究结果表明,心律失常、CHF、超重、肥胖、慢性阻塞性肺病和动脉瘤直径超过 7 厘米是影响 F/BEVAR 术后 5 年生存率的最相关术前因素。更具体地说,心房颤动和心律失常应被用来改变患者的选择,并确定那些更有可能从修复术中获益的患者。此外,在 F/BEVAR 术前监测期间减轻体重和戒烟等可改变的风险因素可能会提高这类人群的存活率。考虑到许多患者在术前会定期接受血管外科团队的评估,直到动脉瘤直径达到修复标准,因此采用多学科方法来解决这些可改变的风险因素可能是一种有影响力的策略。
{"title":"Impact Of Preoperative Risk Factors On 5-year Survival After Fenestrated/Branched Endovascular Aortic Repair.","authors":"Vivian Carla Gomes, F Ezequiel Parodi, Sydney E Browder, Fernando Motta, Priya Vasan, Dichen Sun, William A Marston, Luigi Pascarella, Katharine L McGinigle, Jacob C Wood, Mark A Farber","doi":"10.1016/j.jvs.2024.11.002","DOIUrl":"https://doi.org/10.1016/j.jvs.2024.11.002","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate which preoperative factors most impact the 5-year survival of patients undergoing fenestrated/branched endovascular aortic repair (F/BEVAR) and to identify modifiable elements that, if time allows, should be actively managed and adequately controlled preoperatively.</p><p><strong>Methods: </strong>Patients treated for aortic aneurysms with complex anatomy using either a patient-specific company manufactured or an off-the-shelf F/BEVAR devices were included. The exposure of interest was aneurysm type (group I: types I-III thoracoabdominal aneurysms (TAAA) vs group II: type IV TAAA vs group III: juxtarenal or suprarenal aneurysms) and the primary outcome was 5-year risk of all-cause mortality. Generalized linear models were used to estimate each group's crude 5-year risk of death and the 5-year risk of death across groups. Each preoperative factor was added to the model individually and a change in estimate was calculated between the new risks and the crude risk. Preoperative factors with a change of estimate of ≥10% were utilized to create an inverse probability of treatment weights for multivariable analysis.</p><p><strong>Results: </strong>Results: 408 F/BEVAR patients were included, who were 71.6% male (mean age: 72.0±7.9 years). Eleven of the 22 preoperative factors analyzed had a change in estimate ≥10%. The greatest changes in estimates were observed for history of congestive heart failure (CHF), arrhythmia, overweight, obesity, COPD. Almost 60% of patients with CHF in group I died within 5 years. Current smoking or overweight at the time of F/BEVAR increases the 5-year risk of death more significantly than having a history of myocardial infarction. After adjustment, patients in group I had a significantly higher risk of 5-year all-cause mortality compared to those in group III (log-rank p-value=0.0082).</p><p><strong>Conclusions: </strong>The present findings suggest that cardiac arrhythmias, CHF, overweight, obesity, COPD, and aneurysm diameter above 7 cm are the most relevant preoperative elements that impact the 5-year survival post F/BEVAR. More specifically, CHF and arrhythmias should be used to alter patient selection and identify those individuals more likely to benefit from repair. Moreover, modifiable risk factors such as weight loss and smoking cessation during the surveillance period before the F/BEVAR procedure, might improve survival in this population. Considering that preoperatively, many patients are periodically evaluated by a vascular surgery team until the aneurysm diameter meets criteria for repair, a multidisciplinary approach that could address these modifiable risk factors might be an impactful strategy.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilization of percutaneous closure devices for large bore arterial access in patients with genetic aortopathy does not result in increased rates of access site complications. 在遗传性主动脉病变患者的大口径动脉通路中使用经皮闭合装置不会增加通路部位并发症的发生率。
IF 3.9 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-09 DOI: 10.1016/j.jvs.2024.11.001
Rebecca Sorber, Sasha Smerekanych, Haley J Pang, Blake E Murphy, Kirsten Dansey, Matthew P Sweet, Sara L Zettervall
<p><strong>Objective: </strong>Percutaneous closure devices for arterial sheaths of sufficient caliber to deliver aortic endografts have a published success rate of 90-95%. Despite this, they are frequently avoided in patients with genetic aortopathy due to concern for high failure rates and increased complications in the setting of compromised tissue integrity. This study aims to compare rates of access site complications following large bore percutaneous access among patients with and without confirmed genetic aortopathy.</p><p><strong>Methods: </strong>All patients undergoing endovascular aortic procedures requiring large bore (≥9Fr) femoral sheath access between 2019-2023 were identified. The specific mutation, demographics, comorbidities, and operative details including maximum sheath size were recorded. Outcomes including unplanned femoral cutdown, access site complications and reinterventions were evaluated. These factors were then compared between patients with and without a laboratory confirmed mutation associated with genetic aortopathy. A supplemental analysis was then performed on all patients with genetic aortopathy from 2014-2023.</p><p><strong>Results: </strong>Among the 404 patients identified, 33 (8%) had confirmed genetic aortopathy. Among these, 7 patients (21%) had Marfan syndrome, 7 (21%) had Loeys-Dietz syndrome, and 3 (9%) had vascular Ehlers-Danlos. Also represented were ACTA2, PRKG1, FOXE3, and LOX mutations. The genetic aortopathy group was significantly younger (median genetic aortopathy: median 52 years; non-genetic aortopathy: 71 years; p<0.001). TEVAR was most frequent in the genetic aortopathy group (52%), followed by Zone II arch replacement with frozen elephant trunk (21%); the most frequent operation among the non-genetic aortopathy group was F/BEVAR(43%), followed by TEVAR (25%). Both groups had a median sheath size of 20 Fr; the patients with genetic aortopathy had higher rates of both prior open (genetic aortopathy: 27%; non-genetic aortopathy: 12%; p=0.015) and prior percutaneous ipsilateral access (genetic aortopathy: 58%; non-genetic aortopathy: 39%; p=0.041). Rates of unplanned cutdowns (genetic aortopathy: 0%; non-genetic aortopathy: 6%) and access site complications (genetic aortopathy: 0%; non-genetic aortopathy: 8%) did not significantly differ between groups (p=0.160 and p=0.096, respectively). In supplementary analysis, there was one patient with genetic aortopathy who required unplanned cutdown, yielding an overall technical success rate of 97% for percutaneous closure over a 10-year period.</p><p><strong>Conclusions: </strong>Percutaneous access is safe and effective in patients with confirmed genetic aortopathy with similar rates of unplanned cutdown as those in patients without genetic aortopathy. Given the high rates of staged, repeat aortic procedures in this patient population, percutaneous closure should be attempted to avoid an obligate femoral incision, thereby reducing the potential for wo
目的:用于足够口径动脉鞘的经皮闭合装置可输送主动脉内移植物,已公布的成功率为 90-95%。尽管如此,由于担心高失败率和在组织完整性受损的情况下并发症增加,遗传性主动脉病变患者经常避免使用这些装置。本研究旨在比较已确诊和未确诊遗传性主动脉病变的患者在接受大口径经皮入路手术后入路部位并发症的发生率:方法:对2019-2023年间所有接受血管内主动脉手术、需要大口径(≥9Fr)股骨鞘入路的患者进行鉴定。记录了特定突变、人口统计学、合并症和手术细节,包括最大鞘管尺寸。对结果进行了评估,包括非计划性股骨切开、入路部位并发症和再干预。然后将这些因素在有和没有实验室证实的遗传性主动脉病变突变的患者之间进行比较。然后对 2014-2023 年间所有遗传性主动脉病变患者进行了补充分析:在已确认的 404 名患者中,33 人(8%)确诊患有遗传性大动脉病变。其中,7 名患者(21%)患有马凡综合征,7 名患者(21%)患有 Loeys-Dietz 综合征,3 名患者(9%)患有血管性 Ehlers-Danlos 综合征。此外,还有 ACTA2、PRKG1、FOXE3 和 LOX 突变。遗传性大动脉病变组明显更年轻(遗传性大动脉病变中位数:52岁;非遗传性大动脉病变:71岁;P结论:经皮入路对于确诊的遗传性大动脉病患者是安全有效的,非计划切管率与非遗传性大动脉病患者相似。鉴于这类患者分期、重复进行主动脉手术的比例很高,因此应尝试经皮闭合手术,以避免强制性股骨切口,从而降低伤口并发症的可能性,并增加未来手术的便利性。
{"title":"Utilization of percutaneous closure devices for large bore arterial access in patients with genetic aortopathy does not result in increased rates of access site complications.","authors":"Rebecca Sorber, Sasha Smerekanych, Haley J Pang, Blake E Murphy, Kirsten Dansey, Matthew P Sweet, Sara L Zettervall","doi":"10.1016/j.jvs.2024.11.001","DOIUrl":"https://doi.org/10.1016/j.jvs.2024.11.001","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Percutaneous closure devices for arterial sheaths of sufficient caliber to deliver aortic endografts have a published success rate of 90-95%. Despite this, they are frequently avoided in patients with genetic aortopathy due to concern for high failure rates and increased complications in the setting of compromised tissue integrity. This study aims to compare rates of access site complications following large bore percutaneous access among patients with and without confirmed genetic aortopathy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;All patients undergoing endovascular aortic procedures requiring large bore (≥9Fr) femoral sheath access between 2019-2023 were identified. The specific mutation, demographics, comorbidities, and operative details including maximum sheath size were recorded. Outcomes including unplanned femoral cutdown, access site complications and reinterventions were evaluated. These factors were then compared between patients with and without a laboratory confirmed mutation associated with genetic aortopathy. A supplemental analysis was then performed on all patients with genetic aortopathy from 2014-2023.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among the 404 patients identified, 33 (8%) had confirmed genetic aortopathy. Among these, 7 patients (21%) had Marfan syndrome, 7 (21%) had Loeys-Dietz syndrome, and 3 (9%) had vascular Ehlers-Danlos. Also represented were ACTA2, PRKG1, FOXE3, and LOX mutations. The genetic aortopathy group was significantly younger (median genetic aortopathy: median 52 years; non-genetic aortopathy: 71 years; p&lt;0.001). TEVAR was most frequent in the genetic aortopathy group (52%), followed by Zone II arch replacement with frozen elephant trunk (21%); the most frequent operation among the non-genetic aortopathy group was F/BEVAR(43%), followed by TEVAR (25%). Both groups had a median sheath size of 20 Fr; the patients with genetic aortopathy had higher rates of both prior open (genetic aortopathy: 27%; non-genetic aortopathy: 12%; p=0.015) and prior percutaneous ipsilateral access (genetic aortopathy: 58%; non-genetic aortopathy: 39%; p=0.041). Rates of unplanned cutdowns (genetic aortopathy: 0%; non-genetic aortopathy: 6%) and access site complications (genetic aortopathy: 0%; non-genetic aortopathy: 8%) did not significantly differ between groups (p=0.160 and p=0.096, respectively). In supplementary analysis, there was one patient with genetic aortopathy who required unplanned cutdown, yielding an overall technical success rate of 97% for percutaneous closure over a 10-year period.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Percutaneous access is safe and effective in patients with confirmed genetic aortopathy with similar rates of unplanned cutdown as those in patients without genetic aortopathy. Given the high rates of staged, repeat aortic procedures in this patient population, percutaneous closure should be attempted to avoid an obligate femoral incision, thereby reducing the potential for wo","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PROGNOSTIC IMPACT OF JUXTA-RENAL INNER VESSEL DIAMETER AND VERTICAL DISTANCE IN RENAL ARTERY OUTCOMES AFTER FENESTRATED ENDOVASCULAR REPAIR. 肾动脉内径和垂直距离对肾动脉瓣膜内血管修补术后预后的影响。
IF 3.9 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-08 DOI: 10.1016/j.jvs.2024.10.071
L Mezzetto, N Tsilimparis, M G D'Oria, S Lepidi, R Giudice, C Ferrer, G Bravo, M Antonello, M Piazza, G F Veraldi

Aim: The aim of this retrospective multicenter study is to evaluate the impact of juxta-renal inner vessel diameter (JR-IVD) and vertical distance between renal arteries (RA-VerDi) on renal artery instability (RAI) and associated complications in patients undergoing fenestrated endovascular aortic repair (FEVAR) for complex aortic pathology.

Methods: Patients undergoing FEVAR with custom-made stent grafts at six referral hospitals between 2017 and 2023 were included. Data on patient demographics, anatomical characteristics, stent configurations, and outcomes were collected. Patients were divided into tertiles and categorized into three groups: JR-IVD <20mm, JR-IVD 20-24mm, and JR-IVD >24mm. RA-VerDi was determined by measuring the distance between the center of the lowest renal artery and the highest renal artery, based on the planning specifications for each custom-made graft. The primary outcome was freedom from RAI, with secondary outcomes including renal artery stenosis/occlusion, endoleak, and reintervention. Statistical analyses were performed using MedCalc software, with logistic regression and Kaplan-Meier survival curves employed to assess outcomes.

Results: In total, 520 RAs among 260 patients were analyzed. The technical success rate was 98.7%, with a 30-day mortality rate of 2.3%. After a mean follow-up of 26.9 months (±28.1, range 1-154), RAI was observed in 5.6% of cases, including stenosis/occlusion (3.2%) and endoleak (2.2%). Freedom from RAI at 12, 24, and 48 months was 95.8% (SE 0.01), 93.5% (SE 0.01), and 90.7% (SE 0.01), respectively. JR-IVD <20 mm was identified as a significant risk factor for renal artery stenosis/occlusion (p=0.01), though it did not increase the risk of RAI or reintervention compared to larger JR-IVDs. A correlation was found between RA-VerDi and RAI, with smaller vertical distances associated with higher RAI risk (OR: 0.89, 95% CI: 0.82-0.99, p=0.05), but no significant cutoff was determined. Severe renal artery stenosis was an independent predictor of RAI (OR: 13.28, 95% CI: 3.1-55.86, p=0.004).

Conclusions: The use of fenestrated custom-made grafts in patients with JR-IVD <20 mm may increase the risk of renal artery complications, particularly stenosis/occlusion. Although a correlation between RA-VerDi and RAI was observed, a definitive predictive cutoff could not be established. Attention should be given to patients with severe renal artery stenosis, as this condition seems to be an independent predictor of RAI.

目的:这项回顾性多中心研究旨在评估因复杂主动脉病变而接受开孔血管内主动脉修复术(FEVAR)的患者中,并肾血管内径(JR-IVD)和肾动脉间垂直距离(RA-VerDi)对肾动脉不稳定性(RAI)及相关并发症的影响:纳入2017年至2023年期间在六家转诊医院接受定制支架移植物FEVAR手术的患者。收集了有关患者人口统计学、解剖学特征、支架配置和预后的数据。患者被分为三等分,并分为三组:JR-IVD 24mm。RA-VerDi 是根据每个定制移植物的规划规格,通过测量最低肾动脉中心与最高肾动脉中心之间的距离确定的。主要结果是无 RAI,次要结果包括肾动脉狭窄/闭塞、内漏和再介入。统计分析使用 MedCalc 软件进行,采用逻辑回归和 Kaplan-Meier 生存曲线评估结果:结果:共分析了 260 名患者中的 520 例 RA。技术成功率为 98.7%,30 天死亡率为 2.3%。平均随访 26.9 个月(±28.1,范围 1-154)后,5.6% 的病例观察到 RAI,包括狭窄/闭塞(3.2%)和内漏(2.2%)。在 12、24 和 48 个月时,RAI 的治愈率分别为 95.8%(SE 0.01)、93.5%(SE 0.01)和 90.7%(SE 0.01)。JR-IVD 的结论:在 JR-IVD 患者中使用栅栏式定制移植物
{"title":"PROGNOSTIC IMPACT OF JUXTA-RENAL INNER VESSEL DIAMETER AND VERTICAL DISTANCE IN RENAL ARTERY OUTCOMES AFTER FENESTRATED ENDOVASCULAR REPAIR.","authors":"L Mezzetto, N Tsilimparis, M G D'Oria, S Lepidi, R Giudice, C Ferrer, G Bravo, M Antonello, M Piazza, G F Veraldi","doi":"10.1016/j.jvs.2024.10.071","DOIUrl":"https://doi.org/10.1016/j.jvs.2024.10.071","url":null,"abstract":"<p><strong>Aim: </strong>The aim of this retrospective multicenter study is to evaluate the impact of juxta-renal inner vessel diameter (JR-IVD) and vertical distance between renal arteries (RA-VerDi) on renal artery instability (RAI) and associated complications in patients undergoing fenestrated endovascular aortic repair (FEVAR) for complex aortic pathology.</p><p><strong>Methods: </strong>Patients undergoing FEVAR with custom-made stent grafts at six referral hospitals between 2017 and 2023 were included. Data on patient demographics, anatomical characteristics, stent configurations, and outcomes were collected. Patients were divided into tertiles and categorized into three groups: JR-IVD <20mm, JR-IVD 20-24mm, and JR-IVD >24mm. RA-VerDi was determined by measuring the distance between the center of the lowest renal artery and the highest renal artery, based on the planning specifications for each custom-made graft. The primary outcome was freedom from RAI, with secondary outcomes including renal artery stenosis/occlusion, endoleak, and reintervention. Statistical analyses were performed using MedCalc software, with logistic regression and Kaplan-Meier survival curves employed to assess outcomes.</p><p><strong>Results: </strong>In total, 520 RAs among 260 patients were analyzed. The technical success rate was 98.7%, with a 30-day mortality rate of 2.3%. After a mean follow-up of 26.9 months (±28.1, range 1-154), RAI was observed in 5.6% of cases, including stenosis/occlusion (3.2%) and endoleak (2.2%). Freedom from RAI at 12, 24, and 48 months was 95.8% (SE 0.01), 93.5% (SE 0.01), and 90.7% (SE 0.01), respectively. JR-IVD <20 mm was identified as a significant risk factor for renal artery stenosis/occlusion (p=0.01), though it did not increase the risk of RAI or reintervention compared to larger JR-IVDs. A correlation was found between RA-VerDi and RAI, with smaller vertical distances associated with higher RAI risk (OR: 0.89, 95% CI: 0.82-0.99, p=0.05), but no significant cutoff was determined. Severe renal artery stenosis was an independent predictor of RAI (OR: 13.28, 95% CI: 3.1-55.86, p=0.004).</p><p><strong>Conclusions: </strong>The use of fenestrated custom-made grafts in patients with JR-IVD <20 mm may increase the risk of renal artery complications, particularly stenosis/occlusion. Although a correlation between RA-VerDi and RAI was observed, a definitive predictive cutoff could not be established. Attention should be given to patients with severe renal artery stenosis, as this condition seems to be an independent predictor of RAI.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Vascular Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1